What is ACTU stock price today?

ACTU (Actuate Therapeutics Inc) stock is trading at $5.50 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ACTU stock going up or down today?

ACTU stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ACTU stock now?

The decision to buy ACTU depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ACTU a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ACTU based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ACTU stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ACTU is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ACTU's P/E ratio?

P/E ratio data for ACTU will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ACTU's market cap?

ACTU (Actuate Therapeutics Inc) has a market capitalization of $0.14 billion, making it a small-cap stock.

What is ACTU's price to book ratio?

ACTU trades at a price-to-book (P/B) ratio of 12.09, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ACTU pay dividends?

ACTU does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ACTU's dividend yield?

ACTU does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ACTU stock a good long-term investment?

ACTU's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ACTU's revenue growth rate?

Revenue growth data for ACTU is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ACTU are available on our dashboard with complete income statement analysis.

What are the risks of investing in ACTU?

Key risks for ACTU include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ACTU compare to its competitors?

Compare ACTU to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ACTU's performance and positioning.

What is ACTU's stock price target for 2026?

Our AI model provides price targets for ACTU based on fundamental analysis: Bull case $7.14 (+30%), Base case $6.32 (+15%), Bear case $4.95 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ACTU?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ACTU. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ACTU's next earnings report?

ACTU reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ACTU - Actuate Therapeutics Inc

NYSE * Health Care * Biotechnology

$5.50

$-0.20 (-3.43%)

About Actuate Therapeutics Inc

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

ACTU Key Statistics

Market Cap

$136.67M

P/B Ratio

12.09

EPS

$-3.11

Employees

How ACTU Compares to Peers

ACTU is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ACTU(This stock)	$136.67M	N/A	0%	0.0%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.12B	15.0	0%	0.2%	vs BIIB

Actuate Therapeutics Inc Company Information

Headquarters: Texas; U.S.A
Website: www.actuatetherapeutics.com
Sector: Health Care
Industry: Biotechnology

Data Updated: January 20, 2026 at 10:23 PM EST

Ready to invest in ACTU?

Commission-free trading available. Affiliate links.

ACTU Lician Score

5% confidence

4.0/10

Neutral

ACTU has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ACTUacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ACTU Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ACTU

Dashboard

Enter a ticker to analyze